NCT00001282View on ClinicalTrials.gov

A Phase I/II Study of the Combination of Azidothymidine and Interleukin-2 (IL-2) in the Treatment of HIV-Infected Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 1991

Study Completion Date

April 30, 2002

Conditions

HIV Infection

Interventions

DRUG

Zidovudine (AZT) & Interleukin-2 (IL2)

Trial Locations (1)

20892

National Institute of Allergy and Infectious Diseases (NIAID), Bethesda

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00001282 - A Phase I/II Study of the Combination of Azidothymidine and Interleukin-2 (IL-2) in the Treatment of HIV-Infected Patients | Biotech Hunter | Biotech Hunter